ASMF/CEP Submissions

Freyr empowers API manufacturers with strategic ASMF and CEP submission support, ensuring efficient navigation of EU Regulatory requirements. Our comprehensive services streamline documentation processes, minimize approval delays, and facilitate ongoing compliance.

ASMF/CEP Submissions - Overview

Active Substance Master Files (ASMFs) contain detailed information on the manufacture and properties of active substances and are, therefore, valuable and confidential. The ASMF ensures the protection of the manufacturer’s intellectual property and allows applicants and Marketing Authorization Holders (MAHs) to undertake responsibility for the medicinal product and the quality of the active substance. 

Active Substance Master Files should be presented in the CTD format and are usually divided into two (02) separate parts based on the confidentiality of the content. Information that is considered by the ASMF holder to be non-confidential to the applicant/MAH is contained in the Applicant’s Part (AP), and information considered to be confidential is included in the Restricted Part (RP). The EMA guideline on the Active Substance Master File procedure must be followed to submit ASMFs in compliance with Health Authority (HA) requirements. The submissions must be accompanied by other documentation as specified in the guideline (e.g., Quality Overall Summary (QOS) and Letter of Access).

Manufacturers of substances in the European Pharmacopoeia (Ph. Eur.) can apply for a Certificate of Suitability (CEP). The EDQM guidance on the process for applying for a Certificate of Suitability (CEP). includes the submission of a CTD formatted dossier and a QOS. If a CEP is available for an active substance, companies can use this document instead of an ASMF, thus simplifying the active substance documentation required for medicinal product applications. This can also streamline some active substance-related post-approval changes that can arise during the lifecycle of the product.

Freyr’s Regulatory expertise in the compilation, review, and submission of Active Substance Master Files (ASMFs) and Certificate of Suitability (CEP) submission process in line with the EU and national submission procedures makes it a preferred Regulatory partner for Active Pharmaceutical Ingredients (APIs) and medicinal product manufacturers.

ASMF/CEP Submissions - Expertise

  • Identifying the starting materials.
  • Designing limits for impurities in starting materials, intermediates, and their potential carry-over to drug substances.
  • Designing specifications and in-process limits for starting materials, intermediates, and drug substances.
  • Setting the strategy and limits for genotoxic impurities and elemental impurities in intermediates or drug substances.
  • Guidance on designing the protocols for stability studies, process validation, hold-time studies, and forced degradation studies.
  • Gap analysis of source documents/data generated for ASMF submissions in line with the current guidelines.
  • The preparation and submission of ASMFs and Certificate of Suitability (CEP) applications (including support for the CEP sister-file procedure).
  • Publishing of ASMFs and EU CEP applications in the eCTD format as per the current guidelines and requirements.
  • Lifecycle management and maintenance of the existing ASMFs and CEPs.
  • Regulatory strategy support, including preparation and submission of responses to HA queries.
ASMF/CEP Submissions

Celebrating Customers Success

 

Medicinal Products

Regulatory Affairs

India

Thank you for the timely support over the weekend, which allowed us to resubmit quickly after being notified. This continuously demonstrates Freyr's commitment towards our company’s milestones.

Director - Global Regulatory Affairs – Operations

India-based, Global Top Generic Pharma Company

 

Medicinal Products

Publishing

UK

I am sure you have heard by now that we have received our first-ever approval from the FDA for our Brands division. This is a major milestone for us as well as for my team here in Reg Ops. I would be remiss if I didn’t point out that we would not have been able to do this without the help of your dedicated team. From the original filing, then the following year of responses, all helped get us to final approval.

Thank you Freyr team for a job well done!

Sr. Director, Head of Regulatory Operations

Ireland-based, Global Specialty Pharmaceutical Company

 

Medicinal Products

Regulatory Affairs

USA

Please relate to the team the excellent job they have done on the IND reactivation. Specifically, the high-quality module 3, written by Freyr. It was very comprehensive, very few revisions were required, and we had no questions from Health Canada or FDA. No CMC questions: that was a first for me. So very responsive to my many requests, which I am sure can be frustrating but always helpful while producing excellent work.

Thank you for always being available and responding quickly and comprehensively to all my requests.

What a great team you have, Freyr.

Lynne McGrath

Regulatory Consultant

 

Medicinal Products

Regulatory Affairs

USA

Congratulations!!! ​

Thanks for your great support for a successful ANDA filing, especially to the publishing team. Heartfully appreciate their last hours of hard work.

Assistant Manager​

US-based, Leading, Complex Generic Pharmaceutical Products Company​

 

Medicinal Products

Regulatory Affairs

USA

Thank you all for the great support!​

CEO

US-based, Leading Innovative Pharmaceuticals Company​

 

Medicinal Products

Regulatory Affairs

USA

The ANDA receipt has been received! Thank you very much for your hard work, patience, and support for our work over the last couple of months. We are delighted that we were able to meet the timeline and hit an important corporate goal of our young company. ​

Thank you again, and we look forward to working with your team on the next project!

Senior Director of Business and Product Development​

US-based, Leading Innovator Pharmaceuticals Company​